Decipher Labs Ltd
Incorporated in 1986, Decipher Labs Ltd deals in trading and manufacturing of Pharmaceutical drugs and provides services and key solutions in Information Technology.
- Market Cap ₹ 16.6 Cr.
- Current Price ₹ 16.5
- High / Low ₹ 25.8 / 14.5
- Stock P/E
- Book Value ₹ 20.4
- Dividend Yield 0.00 %
- ROCE 9.72 %
- ROE 16.2 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 0.80 times its book value
- Company has a good return on equity (ROE) track record: 3 Years ROE 29.8%
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 16.4%
- Promoter holding has decreased over last 3 years: -29.5%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
|---|---|---|---|---|---|---|---|
| 1.02 | 8.06 | 23.99 | 55.56 | 65.32 | 45.57 | 35.07 | |
| 0.95 | 7.61 | 21.47 | 52.08 | 59.29 | 49.66 | 41.10 | |
| Operating Profit | 0.07 | 0.45 | 2.52 | 3.48 | 6.03 | -4.09 | -6.03 |
| OPM % | 6.86% | 5.58% | 10.50% | 6.26% | 9.23% | -8.98% | -17.19% |
| 0.11 | 0.00 | 0.27 | 0.65 | 7.67 | 0.84 | 0.30 | |
| Interest | 0.00 | 0.01 | 0.77 | 1.17 | 0.48 | 0.48 | 0.08 |
| Depreciation | 0.00 | 0.00 | 0.56 | 0.82 | 0.87 | 0.43 | 0.46 |
| Profit before tax | 0.18 | 0.44 | 1.46 | 2.14 | 12.35 | -4.16 | -6.27 |
| Tax % | 0.00% | 9.09% | 25.34% | 34.58% | 7.85% | 35.58% | |
| 0.18 | 0.41 | 1.10 | 1.40 | 11.38 | -2.68 | -7.15 | |
| EPS in Rs | 0.22 | 0.51 | 1.09 | 1.39 | 11.27 | -2.65 | -7.08 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 114% |
| 3 Years: | 24% |
| TTM: | -41% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 85% |
| 3 Years: | 52% |
| TTM: | -302% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | -9% |
| 3 Years: | -24% |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 30% |
| Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 8.00 | 8.00 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 |
| Reserves | -5.88 | -5.47 | 2.46 | 3.59 | 14.07 | 13.11 | 10.50 |
| 0.13 | 0.20 | 11.28 | 16.39 | 10.32 | 0.95 | 0.00 | |
| 0.71 | 3.61 | 11.55 | 8.64 | 7.46 | 4.01 | 3.33 | |
| Total Liabilities | 2.96 | 6.34 | 35.39 | 38.72 | 41.95 | 28.17 | 23.93 |
| 0.00 | 0.01 | 4.98 | 4.43 | 2.83 | 3.31 | 3.13 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.38 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.26 | 3.76 | 0.00 |
| 2.96 | 6.33 | 30.41 | 34.29 | 38.86 | 21.10 | 17.42 | |
| Total Assets | 2.96 | 6.34 | 35.39 | 38.72 | 41.95 | 28.17 | 23.93 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|---|
| -0.10 | 0.23 | -15.18 | 1.83 | 8.26 | -1.56 | |
| 0.00 | -0.02 | -0.01 | -0.31 | -1.13 | -4.28 | |
| 0.09 | 0.07 | 16.36 | 3.99 | 1.30 | -2.15 | |
| Net Cash Flow | -0.01 | 0.28 | 1.17 | 5.51 | 8.43 | -7.99 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|---|
| Debtor Days | 211.13 | 156.69 | 222.44 | 76.67 | 71.47 | 78.90 |
| Inventory Days | 91.25 | 19.70 | ||||
| Days Payable | 511.00 | 192.66 | ||||
| Cash Conversion Cycle | -208.62 | -16.27 | 222.44 | 76.67 | 71.47 | 78.90 |
| Working Capital Days | 797.99 | 108.68 | 146.97 | 4.99 | 85.83 | 69.28 |
| ROCE % | 18.07% | 16.79% | 12.28% | 39.74% | 9.72% |
Documents
Announcements
- Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 20 Apr
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 19 Apr
- Compliance As Per Regulation 40 (10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended 31.03.2024. 15 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
15 Apr - Compliance certificate as per Regulation 74(5) of SEBI(DP) Regulations, 2018 for the quarter ended 31.03.2024
- Compliance Certificate For The Period Ended 31.03.2024 15 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Services Offered:[1][2]
a) Pharmaceuticals: Manufacturing & Marketing of Branded Formulations and Custom Manufacturing for companies. Company also caters to various formulators, manufacturers and Research and Development agencies for their Bulk needs and sources and supplies various drugs and allied products & services to companies upon request.
b) Information Technology: Company has taken over Decipher Software Solutions LLC in USA which is an Information Technology services firm, specializing in ERP Implementation, Mobile & Cloud solutions, Product Development, Offshore Services, Technology Integration and Systems Consulting, Software Development Consulting and Management of IT projects.